Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.

Mrinal M Gounder,Todd M Bauer,Gary K Schwartz,Amy M Weise,Patricia LoRusso,Prasanna Kumar,Ben Tao,Ying Hong,Parul Patel,Yasong Lu,Arnaud Lesegretain,Vijaya G Tirunagaru,Feng Xu,Robert C Doebele,David S Hong

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

Cited 14|Views34
No score
Abstract
An intermittent dosing schedule of 3/14 days of milademetan mitigates dose-limiting hematologic abnormalities while maintaining efficacy. Notable single-agent activity with milademetan in dedifferentiated liposarcomas has prompted a randomized phase III trial (MANTRA).
More
Translated text
Key words
mdm2 inhibitor,advanced liposarcoma,milademetan,solid tumors,first-in-human
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined